Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) Tablets
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
February 2016
ADVERSE REACTIONS
Postmarketing
Weight increased
DRUG INTERACTIONS
Hepatitis C Antiviral Agents:
...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts